CD19 CAR T cell therapy (Gracell Biotechnology)

N/A

Report date: 2025/12/19 20:01:35

Base Information

Drug NameCD19 CAR T cell therapy (Gracell Biotechnology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-CellBurkitt Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGracell Biotechnology Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia, B-CellBurkitt Lymphoma

Other Information

ATC CodeN/A